Clinical Trial Update: T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab monotherapy guided by a T cell inflamed gene expression profiling score for refractory solid tumors in patients not previo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Refractory Solid Cancer Patients Unexposed to Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING